Drug Search Results
More Filters [+]

ALX-0651

Alternative Names: alx-0651, alx0651, alx 0651
Latest Update: 2012-04-17
Latest Update Note: Clinical Trial Update

Product Description

CXCR4-inhibitor (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01374503)

Mechanisms of Action: CXCR4 Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ALX-0651

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Alcoholism

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2006-7041-83/hah

P2

Not yet recruiting

Alcoholism

2022-09-01

ALX-0651-1.1/11

P1

Terminated

Healthy Volunteers

2012-01-01

Recent News Events

Date

Type

Title